#1Company overview Financial review 2023 priorities Appendix Q4 2022 Results Investor presentation U NOVARTIS | Reimagining Medicine#2Company overview Financial review 2023 priorities Appendix Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group's liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding the conclusion of the strategic review of Sandoz, our planned 100% spin-off of Sandoz, through which we plan to become a fully focused Innovative Medicines business. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the benefits and opportunities expected from our planned 100% spin-off of Sandoz may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Ibrance® is a registered trademark of Pfizer Inc. 2 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#3Company overview Financial review 2023 priorities Appendix Vas Narasimhan, M.D. Chief Executive Officer Company overview 3 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#4Company overview Financial review 2023 priorities Appendix Novartis delivers robust core operating income growth and core margin expansion; achieves important innovation milestones STRATEGY Growth, cc Group sales Q4 +3% (FY +4%) IM sales Q4 +3% (FY +4%); US IM sales Q4 +7% Sandoz sales Q4 +0% (FY +4%) 1 Innovation Pluvicto EU approval for mCRPC post-taxane Iptacopan Ph3 APPOINT-PNH met primary endpoint Pluvicto Ph3 PSMAfore in mCRPC pre-taxane met primary endpoint lanalumab Ph3 initiated in wAIHA; Ph3 initiating in 1L ITP and 2L ITP 3 Productivity, cc Group core operating income Q4 +15% (FY +8%) IM core operating income Q4 +14% (FY +8%) IM core margin Q4 36.4%, +3.5%pts (FY 36.9%) Sandoz core operating income Q4 -18% (FY -1%) SG&A savings of ~USD 1.5bn to be fully embedded by 20242 2 ESG 4 Sustainability Linked Bond: Significant progress towards 2025 targets Innovative Therapies in LMICS: ~1.2m patients; +26.3% vs. 2021 Novartis flagship programs: ~31m patients vs. 2025 target ~23m Ratings: CDP - AA score¹; ATMI: Leaders group 10th consecutive year Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. IM - Innovative Medicines division. mCRPC metastatic castration-resistant prostate cancer. WAIHA - warm autoimmune hemolytic anemia. ITP immune thrombocytopenia. LMIC low and middle income countries. CDP carbon disclosure project. ATMI - Access to Medicine Index. 1. One of only two pharma companies with AA rating. 2. Relating to streamlined organizational model. 4 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#5Company overview Financial review 2023 priorities Appendix New Novartis¹: Our focused strategy Focusing on high-value innovative medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches Our focus 5 core Therapeutic Areas² Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology 2 + 3 technology platforms Chemistry, Biotherapeutics XRNA, Radioligand, Gene & Cell Therapy 4 priority geographies US, China, Germany, Japan STRATEGY Our priorities Accelerate growth Deliver returns Strengthen foundations Deliver high-value medicines (including launch excellence) Embed operational excellence Unleash the power of our people Scale data science and technology Build trust with society 1. New Novartis here and in the rest of the presentation refers to Novartis assuming planned Sandoz spin-off. Subject to final Novartis AG BoD and shareholder approval (EGM). 2. Other TAs opportunistically. 5 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#6Company overview Financial review 2023 priorities Appendix As a pure-play Innovative Medicines company, New Novartis is uniquely positioned to leverage its scale, strengths and expertise STRATEGY Novartis is on track to become a pure-play Innovative Medicines company Simplified organizational model allowing for greater focus, leveraging scale and expertise Illustrative Large diversified pharma Divested consumer health JV Jun 2018 Spun Alcon Apr 2019 Announced planned Sandoz spin-off¹ Aug 2022 New Novartis Exited Roche stake 100% Nov 2021 Innovative Medicines 1. Company filings and FactSet. 2. Median P/E (Bloomberg, current year). 6 Investor Relations | Q4 2022 Results Total company revenue¹ N J Large pure-play pharma H New Novartis >$40bn Mid-size diversified M pharma K Diversified pharma² Median P/E 13x Mid-size pure-play pharma A B E D <100% Pharma contribution to total sales1 Pure-play pharma² Median P/E 20x ✓ NOVARTIS | Reimagining Medicine#7Company overview Financial review 2023 priorities Appendix STRATEGY New Novartis expected to continue delivering improved financials New Novartis expectations (illustrative only) Sales % cc, CAGR +4% 2022 2027 Core Operating Income Margin (corporate costs absorbed) -40%+ Incremental benefit from planned Sandoz spin-off Free Cash Flow % of sales 2022 Expected to grow sales, core margin and FCF (% of sales) Margin targets include absorbing corporate costs Planned Sandoz spin-off will result in incremental growth for: 2027 ◉ Core operating income margin " FCF (% of sales) ■ Return on invested capital Return on Invested Capital 2022 2027+ 2022 2027 7 Investor Relations | Q4 2022 Results Remain committed to capital allocation priorities, with growing (CHF) annual dividend NOVARTIS | Reimagining Medicine#8Company overview Financial review 2023 priorities Appendix Focused on five core Therapeutic Areas that have the largest growth potential and leverage our existing assets/expertise STRATEGY Select examples¹ Disease areas (selected) ☐ Cardiovascular ■ Heart failure & hypertension Atherosclerosis Commercial assets sacubitril/valsartan Immunology ■ Psoriasis Psoriatic arthritis Spondylitis/Spondylarthritis Hidradenitis suppurativa ■ CSU Sjögren's / SLE/LN Neuroscience ☐ Multiple sclerosis Spinal muscular atrophy Neurodegeneration, including Parkinson's, ALS Solid Tumors ■ Prostate cancer ■ Breast and Women's cancer Lung cancer Entresto LEQVIO Cosentyx LARIS secukinumab (canakinumab) Kesimpta (ofatumumab) zolgensma 2 Xolair Omalizumab (siponimod) tablets MAYZENT aimovig ferenumab-aco M GILENYA Cingolimod KISQALI ribociclib. Tafinlar +Mekinist (deelenib (ne) Hematology " Non-Hodgkin's Lymphoma Non-malignant hematological - Immune thrombocytopenia ■ Acute myeloid leukemia / Myelodysplastic syndrome PLUVICTO ◆ PIQRAY (alpelis b) tablets x PROMACTA (eltrombopag) KYMRIAH (tisagenlecleucel) SCEMBLIX® (asciminib) 20mg 4 ng tables ⒸJAKAVI ruxolitinib Pipeline Iptacopan (LNP023) assets and C3G, IgAN opportunities Pelacarsen³ (TQJ230) CVRR-Lp(a) Leqvio CVRR-LDLC XXB750 HFPEF, rHT Cosentyx Multiple indications Remibrutinib (LOU064) CSU lanalumab (VAY736) Sjögren's, SLE, LN Ligelizumab (QGE031) Food Allergy Remibrutinib (LOU064) MS OAV101 SMA IT DLX3134 Parkinson's Kisqali Adjuvant HR+/HER2- BC JDQ433 NSCLC NIS793 1L mPDAC / 1L MCRC Pluvicto Prostate cancer Iptacopan (LNP023) PNH, AHUS lanalumab (VAY736) Multiple indications YTB323 Non-Hodgkin's Lymphoma FY Sales USD5 4.8bn 7.3bn 5.1bn 4.7bn 6.5bn 1. TA-x (incl. Ophtha, Resp and other assets) not included in the above list. 2. AimovigⓇ is commercialized by Novartis ex-US/Japan. 3. Pelacarsen is licensed from lonis Pharmaceuticals, Inc. 4. DLX313 is Novartis program name for UCB0599. 5. FY 2022 sales for entire Therapeutic Area. 8 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#9Company overview Financial review 2023 priorities Appendix Our capital allocation priorities are shareholder-focused, allowing for flexibility in strategic investments and capital distribution STRATEGY Investing in the business Investments in organic business USD 9.1bn R&D 20221 USD 1.2bn capital investments 2022 Substantial cash generation Value-creating bolt-ons Returning to shareholders USD 59bn distributed 2018-2022 Growing annual dividend in CHF USD 7.5bn paid out in 2022 Proposed DPS: +3.2% CHF; +3.9% USD No rebasing post planned Sandoz spin-off Share buybacks USD 30bn (approx.) 2018-2022 USD 15bn ongoing USD 4.9bn to be executed² Planned Sandoz spin-off is expected to have limited impact on our credit rating, providing continued flexibility for future capital allocations 1. Core R&D and cap-ex actuals 2022. 2. As of December 31, 2022. 9 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#10Company overview Financial review 2023 priorities Appendix INNOVATION Prioritizing pipeline to high-value innovative medicines Refining our proven development engine with greater focus on asset value and improving R&D productivity Proven development engine Improving R&D productivity Total NME approvals by company (1999-2021)1 42 34 == 1 Clear TA strategy with disease area prioritization 30 NDA 12 BLA 28 20 23 23 18 14 Novartis Company A Company B Company C Company D Company E 2 Early assets with integrated development plans, until submission 3 Ongoing tracking and evaluation of asset progression/value 4 End-to-end governance with clear processes and ownership Expected outcomes Improved overall success rate (discovery to approval) ☐ Cycle time reduction Increased asset value ✓ Industry leader across first-in-class approved NMEs² 1. US FDA NME approvals. 2. FDA: BCG analysis (2017-2021). 10 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#11Company overview Financial review 2023 priorities Appendix Key near-term readouts (2023) for high-value medicines... INNOVATION Key assets* with submission enabling readouts in 2023 KisqaliⓇ NATALEE trial in adjuvant breast cancer testing broad patient population (anatomical stage II and III), with final analysis expected in H2 2023 Iptacopan APPOINT-PNH trial in treatment- naive patients positive readout; detailed data presentation in 2023 PNH FDA submission planned H1 2023 APPLAUSE-IgAN Ph3 readout² planned in H2 2023 APPEAR-C3G Ph3 readout planned in H2 2023 PluvictoⓇ PSMAfore trial in mCRPC (post-ARDT, pre-taxane) positive readout; detailed data presentation planned in 2023 FDA regulatory submission planned H2 2023 * Unprobabilized peak sales of all asset indications in late-stage development: > USD 1bn > USD 2bn > USD 3bn 1. Based on AJCC prognostic staging. 2. 9 months analysis potentially supporting US Subpart H filing. 11 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#12Company overview Financial review 2023 priorities Appendix set to increase in 2024-2025 timeframe INNOVATION Key assets* with submission enabling readouts in 2024-2025 Pelacarsen CVRR Readout and submission in 2025 Iptacopan Additional readouts/submissions in 2025/2026+ lanalumab 1L and 2L ITP readouts in 2025 with submission in 2026 Additional hematology and immunology indications 2026+ PluvictoⓇ MHSPC Readout and submission in 2024 Remibrutinib CSU Readout and submission in 2024 OAV-101 SMA IT Readout in 2024; submission in 2025 ScemblixⓇ 1L CML-CP Readout in 2024; submission in 2025 * Unprobabilized peak sales of all asset indications in late-stage development: > USD 1bn > USD 2bn > USD 3bn 12 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#13Company overview Financial review 2023 priorities Appendix INNOVATION KisqaliⓇ - NATALEE study continues following first interim analysis; final readout expected H2 2023 NATALEE: HR+/HER2- pre- and post-menopausal, early breast cancer Stage II & III | N=5000 R 1:1 3 weeks on/1 week off 36 months KISQALIⓇ Endocrine therapy (NSAI + goserelin³) Endocrine therapy (NSAI + goserelin³) 60 months 60 months Patient population: 218K patients with early breast cancer in US + EU1 NATALEE differentiation Broad population including anatomical Stage II and III² Longer treatment duration of 3 vs. 2 years (monarchE) Lower dose (400mg/day) to potentially improve tolerability and adherence without compromising efficacy Study status Final analysis planned at 500 iDFS events, expected H2 2023 1st interim analysis at 70% of events (completed, study continues) 2nd interim analysis at 85% of events NSAI - non-steroidal aromatase inhibitor. 1. eBC Patient - Adjuvant Breast Cancer Opportunity Assessment June 2020. 2. Based on AJCC prognostic staging. 60% Stage III and 40% Stage II patients in study. Stage II vs. Stage III is a stratification factor. The trial did not require Ki-67% or other CDx for patient identification or stratification, but Ki-67% is part of the statistical analysis plan. 3. In pre-menopausal women and in men. 13 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#14Company overview Financial review 2023 priorities Appendix PluvictoⓇ - PSMAfore study demonstrated statistically significant and clinically meaningful radiographic PFS benefit; filing H2 2023 PSMAfore: Patients with mCRPC who progressed while on ARPI treatment | N=450 PLUVICTOⓇ rPFS ✓ Primary endpoint analysis (at 175 events) Final OS Secondary endpoint analysis 2025 Follow-up period Once every 6 weeks for 6 cycles for additional OS data R 1:1 Change in Androgen Receptor Pathway Inhibitor treatment On a continuous basis rPFS radiographic progression free survival. OS overall survival. mCRPC metastatic castration-resistant prostate cancer. 14 Investor Relations | Q4 2022 Results INNOVATION Study status Met the primary endpoint (rPFS) - statistically significant and clinically meaningful First PSMA-targeted RLT to demonstrate clinical benefit in patients with mCRPC who have not yet received taxane-based chemotherapy FDA regulatory submission planned for H2 2023, to include OS data as aligned with FDA Addressing a significant unmet need in earlier lines of metastatic prostate cancer NOVARTIS | Reimagining Medicine#15Company overview Financial review 2023 priorities Appendix Expanding PluvictoⓇ development program to address significant unmet need in earlier lines and stages of prostate cancer INNOVATION Our ongoing clinical development plan for PluvictoⓇ in prostate cancer Prostate cancer incidence in US, in patients per year Early disease Local PC 283k1 BCR 41k1 Under evaluation Advanced disease nmCRPC 33k1 MHSPC 39k1 PSMAddition (mHSPC) | Primary completion 2024 Late disease mCRPC 1L 42k1 mCRPC 2L+ 27k1 PC prostate cancer. BCR biochemical recurrence. nmCRPC non-metastatic castration-resistant prostate cancer. 1. Source: Kantar 2023 US Prostate Cancer Incidence, as of 30-Jan-2023 15 Investor Relations | Q4 2022 Results PSMAfore (pre-taxane) | Primary completion 2022 VISION (post-taxane) | US/EU approval 2022 mHSPC metastatic hormone-sensitive prostate cancer. mCRPC - metastatic castration-resistant prostate cancer. ✓ NOVARTIS | Reimagining Medicine#16Company overview Financial review 2023 priorities Appendix Iptacopan - provides the opportunity to redefine care across multiple complement-driven conditions¹ INNOVATION 2021 2022 2023 2024 First-in-class, oral, selective factor B inhibitor, targeting complement system proximally via alternative pathway¹ Indication 2025 2026+ Key updates US prevalence Thousands PNH Ph3 - APPLY Ph3-APPOINT Superior to SoC for both primary endpoints in patients with residual anemia despite SoC Achieved clinically meaningful increases in Hb levels in treatment-naive patients with PNH <10 IgAN Ph3 - APPLAUSE C3G Ph3 APPEAR aHUS IC-MPGN * 9 months analysis (H2 2023) potentially provides basis for US Subpart H filing on proteinuria reduction Submission enabling readout H2 2023 1852 <10 Ph3 APPELHUS Submission enabling readout in 2025 <10 Ph3 Ph3 start in H2 2023 <10 Additional ongoing early-stage (Ph2) activities in Lupus Nephritis, iAMD and Immune thrombocytopenia PNH - paroxysmal nocturnalhemoglobinuria. IgAN - immunoglobulin A nephropathy. C3G complement 3 glomerulopathy. aHUS atypical hemolytic uremic syndrome. iAMD - intermediate age-related macular degeneration. IC-MPGN - immune complex membranoproliferative Glomerulonephritis. *9 months readout may support US submission for accelerated approval. 1. Phase 3 studies initiated or planned; additional indications are being explored. 2. Estimated ~46-55k number of patients at high risk of progression with proteinuria > 1g/day (~25-30%). 16 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#17SECONDARY PRIMARY Company overview Financial review 2023 priorities Appendix Iptacopan demonstrated superiority over anti-C5 in adult PNH patients with residual anemia despite anti-C5 treatment... INNOVATION APPLY-PNH: Randomized, active-comparator controlled Ph3 trial in adult PNH patients with residual anemia, despite treatment with an intravenous anti-C5 antibody Endpoints Observed Iptacopan vs. SoC Population estimate² Iptacopan vs. SoC Difference Increase from baseline in Hb of ≥ 2 g/dL 51/601 vs. 0/35 82.3% vs. 2.0% 80.3% (95% CI 71.3, 87.6) P<0.00013 in the absence of RBC transfusions Hb ≥ 12 g/dL 42/601 vs. 0/35 68.8% vs. 1.8% 67.0% (95% CI 56.3, 76.9) P<0.00013 in the absence of RBC transfusions Transfusion avoidance 60/62 vs. 14/35 96.4% vs. 26.1% 70.3% (95% CI 52.6, 84.9) P<0.00013 Clinical breakthrough hemolysis 2/62 vs. 6/35 Rate ratio (95% CI) of 0.10 (0.02, 0.61) means 10-fold lower rate of annualized clinical breakthrough hemolysis Improvements across a range of other secondary endpoints: Increasing Hb, reducing patient-reported fatigue and reticulocyte count, maintaining low LDH 17 Investor Relations | Q4 2022 Results PNH - paroxysmal nocturnal hemoglobinuria. 1. 2/62 patients in the iptacopan arm had missing data between Days 126 and 168 so were not evaluable based on observed data. 2. Marginal proportions reflect the population average probability of a patient meeting the endpoint criteria. 3. P values are two-sided and unadjusted. ✓ NOVARTIS | Reimagining Medicine#18Company overview Financial review 2023 priorities Appendix and showed clinically meaningful increases in Hb levels for treatment-naive adult patients with PNH INNOVATION APPOINT-PNH: Single-arm Ph3 trial in adult patients with PNH with hemolysis (LDH > 1.5x ULN) and anemia (Hb < 10g/dL) naive to complement inhibitors Iptacopan 200mg BID1 Duration Up to 8 weeks- 24 weeks Time D-58 D1 24 weeks D168 D336 EoS Study period Screening period Core treatment period Treatment extension period Study status Met primary endpoint of proportion of patients achieving a sustained increase in Hb of ≥ 2g/dL, in the absence of transfusions, at 24 weeks Safety profile consistent with previously reported data Data to be presented at upcoming medical meeting Iptacopan has the potential to be practice-changing in PNH PNH - paroxysmal nocturnalhemoglobinuria. 1. BID twice daily. 18 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#19Company overview Financial review 2023 priorities Appendix Upcoming 9 months analysis from IgAN Ph3 study (APPLAUSE) could potentially support US Subpart H filing APPLAUSE-IgAN: Biopsy-confirmed patients with IgAN at risk of progression with elevated proteinuria (UPCR1 ≥1g/g) despite being on stable background therapy² Iptacopan 200mg BID³ RE 1:1 Placebo 9 months analysis ↓ I I 24 months 24 months End of study INNOVATION Option to roll over in open-label extension study H2 2023 Enrollment completed Assess superiority in reduction of proteinuria¹ at 9 months Potentially supporting US Subpart H regulatory submission for accelerated approval 2025 Enrollment ongoing Assess superiority in slowing progression of IgAN Submission enabling readout for full approval 1. UPCR (urine protein-to-creatinine ratio) from 24-h urine collection. 2. Including at least maximally tolerated dose of ACEI/ARB for at least 90 days. 3. BID twice daily. 19 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#20Company overview Financial review 2023 priorities Appendix Selected early stage assets with the potential to deliver high-impact medicines for patients INNOVATION Compound Therapeutic area МоА Indication(s) Current phase Next milestone XXB750 Cardiovascular NPR1 agonist Hypertension Ph2b Ph2b readout 2024 Heart failure YTB323 Hematology O CD19 RAPID CART 1L HR LBCL Ph2 Data readout(s) 2024/2025 Immunology Multiple indications being explored AAA603 Solid Tumors Radioligand therapy targeting GRPR Breast cancer Ph1 Ph1 readout - H2 2023 Glioblastoma PPY988 Ophthalmology Gene therapy - Complement factor I modulation Geographic atrophy Ph2b Topline data - 2024 DLX313 Neuroscience a-Synuclein inhibitor Parkinson's Ph2a Topline data - 2024 NPR1 natriuretic peptide receptor 1. CART - chimeric androgen receptor T. LBCL - large B-cell lymphoma. GRPR gastrin releasing peptide receptor. 20 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#21Company overview Financial review 2023 priorities Appendix Confidence in near and mid-term growth underpinned by multi-bn existing medicines and pipeline GROWTH Existing large multi-bn medicines1, USD 13.2bn growing 26% (FY22) Additional multi-bn¹ medicines Select pipeline with multi-bn¹ potential KISQALI zolgensma PLUVICTO™ SCEMBLIX iptacopan (R) Cosentyx Entresto Kesimpta LEQVIO® IN-MARKET remibrutinib pelacarsen ianalumab Additional pipeline assets NEAR-TERM Expected LOE impact greater up to 2025, less thereafter² MID-TERM 1. Potential USD sales. 2. For forecasting purposes, we assume Entresto LOE in 2025. 21 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#22Company overview Financial review 2023 priorities Appendix 2022 driven by particularly strong performance from EntrestoⓇ, KesimptaⓇ, KisqaliⓇ and PluvictoⓇ FY sales¹ Entresto * Sales USD million 4,644 sacubitilvalsartan Kesimpta * (ofatumumab) 1,092 KISQALI✶ 1,231 294 ribociclib * 271 PLUVICTO™ 271 SCEMBLIX * 149 (asciminih) ago 142 * *LEQVIO® 112 100 Tafinlar. Mekinist. 1,770 77 bohrt MAYZENT. 357 (siponimod) tablets 76 ILARIS (canakinumab) 1,133 74 PROMACTA® (eltrombopag) Cosentyx 2,088 72 * 4,788 70 (secukinumab * Please see subsequent slides Growth vs. PY USD million Growth vs. PY CC GROWTH 1,096 720 37% 200% 2022: Strong growth (+60% cc) 38% nm 2023 and beyond: nm Expect continued nm strong growth 11% 32% 15% 9% 5% Expect LCM to accelerate growth Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 50 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. nm - not meaningful. LCM-life cycle management. 22 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#23Company overview Financial review 2023 priorities Appendix EntrestoⓇ delivers strong growth across all geographies Sales evolution USD m, % cc US weekly TRX2 Total prescriptions (000) Ex-US US 100 +44% 90 1,291 80 70 949 597 429 40 30 694 20 520 10 0 Q4 2021 Q4 2022 July 2015 82220 60 50 Jan 2023 GROWTH Entresto Strong Q4 momentum across geographies US: NBRX +16% vs PY, ~1.2m TRx in Q41 EU: continued growth in HFrEF China/Japan: significant contribution from HTN² FY sales 4.6bn (+37% cc, +1.1bn) Confidence in future growth³ US/EU: further penetration in CHF Strong clinical profile and RW data in heart failure China/Japan: launch momentum in HTN TRX - total prescriptions. HFrEF heart failure with reduced ejection fraction. CHF chronic heart failure. RW real world. HTN - hypertension. 1. IQVIA National Prescription Audit. 2. Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US) HFrEF (EU) HFrEF and HTN (China and JP). HTN is not an approved indication in the US. 3. For forecasting purposes, we assume EntrestoⓇ LOE in 2025. 23 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#24Company overview Financial review 2023 priorities Appendix GROWTH Cosentyx® Q4 sales impacted mainly by a revenue deduction true-up related to prior quarters in the US and China COVID lockdowns Sales evolution USD m, % cc Ex-US US -9% / -2%1 +5% 1,243 4,718 4,788 1,080 473 1,835 2,018 447 *Cosentyx® Q4 performance US: -18%-6%. Impacted by a RD true-up relating to prior quarters in 2022 driven primarily by a higher Medicaid channel mix Ex-US: +5% (cc), growth driven by core indications China: Impacted by COVID and stock compensation provision for 2023 NRDL re-listing Volume continues to grow across key geographies FY sales USD 4.8bn (+5% cc) driven by ex-US (+20% cc) Future growth mainly driven by LCM 770 2,883 2,770 633 2021 2022 Q4 2021 2022 2023: Expect sales broadly in line with PY (H2 growth and H1 decline²) 2024+: LCM anticipated to drive next phase of growth FY LCM-life cycle management. RD - revenue deduction. NRDL - national reimbursement drug list. 1. US CosentyxⓇ sales growth was impacted by a revenue deduction true-up, which was related to prior quarters in 2022. Global sales declined -9% in Q4 vs. PY (decline would have been -2% without the true-up). US sales declined -18% in Q4 vs. PY (decline would have been -6% without the true-up). 2. Expect continued RD dynamics in US. 24 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#25Company overview Financial review 2023 priorities Appendix Cosentyx® - life cycle management to drive growth from 2024 Peak sales potential including all existing and new indications > USD 7bn GROWTH *CosentyxⓇ Indication Potential Life cycle development milestones Hidradenitis Suppurativa (HS) 2022 2023 2024 2025 2026 2027 Giant Cell Arteritis (GCA) Lupus Nephritis (LN) 2mL AI/PFS & IV expansion Additional Ph3 indication programs under assessment <USD 1bn USD 1-2bn >USD 2bn Diagnosed population¹ HS IV 2mL AI / PFS GCA Indication Patients Unmet need LN HS >400K GCA >480K Debilitating skin disease with significant QoL impact Eye-sight threatening vasculitis in elderly LN >130K Major cause of morbidity and mortality in SLE patients Primary readout Regulatory decisions expected Ph3 Ph3 EU US US US HS hidradenitis suppurativa. GCA giant cell arthritis. LN- lupus nephritis. Al auto injector. PFS prefilled syringe. IV-intravenous formulation (rheumatology indications). 25 Investor Relations | Q4 2022 Results 1. Total diagnosed population G6 countries. ✓ NOVARTIS | Reimagining Medicine#26Company overview Financial review 2023 priorities Appendix KesimptaⓇ shows strong growth driven by a compelling product profile GROWTH Sales evolution USD m, % cc Ex-US US 66 50 99 289 239 195 147 109 Global sales +28% (cc) vs. Q3, driven by US¹ TRX +116% vs. PY (market +1%) 1,2 369 Q1 Q2 2021 Q3 Q4 Q1 Q2 Q3 Q4 2022 NBRX +43% vs. PY (market -8%) 1,2 B-cell NBRx share about 50% of MS market1,2 KesimptaⓇ B-cell NBRx share ~30% 1,2 Adding ~80-90 new writers/month 1,3 Fast initiation: <6 days for 80% patients 1,4 FY sales USD 1.1bn (+200% cc) Confident in future growth Powerful efficacy: 9/10 patients with NEDA-3 at year 45 Kesimpta Convenience: 1 minute a month dosing from home or anywhere NEDA - No Evidence of Disease Activity 1. Refers to US unless otherwise stated. 2. December 2022, IQVIA NPA (KesimptaⓇ) and IQVIA NPA adjusted by NSP (all others). 3. Data on file. 4. Measured as days between prescription and dispense of first dose. Refers to patients in KesimptaⓇ Patient Support Program. Data on file. 5. Kuhle, et al. Poster 6. The initial dosing period consists of 20 mg subcutaneous doses at Weeks 0, 1 and 2, thereafter once a month. Patient must take pen out of the refrigerator 15-30 minutes before self- TRX total prescriptions. NBRxX new to brand prescription. B-cell therapies as portion of MS market in NBRx. presented at ECTRIMS, 26-28 October, 2022. administering. 26 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#27Company overview Financial review 2023 priorities Appendix GROWTH KisqaliⓇ delivers strong growth across all geographies based on increasing recognition of overall survival and quality of life benefits Sales evolution USD m, % cc Ex-US US +33% 357 285 208 187 149 98 Q4 2021 Q4 2022 KISQALI US MBC NBRx share1 R3M, % 12% Mar 2022 27% Nov 2022 FY sales USD 1.2bn (+38% cc) NBRx share 27%1 NCCN update²: The only Category 1 treatment for 1L mBC with Al; Category 1 for 1L with fulvestrant RIGHT Choice Ph2 study: KisqaliⓇ doubled median PFS in patients with aggressive HR+/HER2- MBC compared to CT3 NATALEE final analysis expected H2 2023 HARMONIA H2H (vs. Ibrance®) recruiting Approved in China for pre/peri-menopausal HR+/HER2- MBC mBC metastatic breast cancer. R3M-rolling 3 months. H2H - head-to-head. 1. Of CDK4/6 mBC market, US Nov'22 R3M. 2. NCCN Guidelines updated as of 27-Jan-2023. 3. RIGHT Choice evaluated Kisqali Ⓡ plus endocrine therapy (ET) vs. combination chemotherapy (CT) in 1L pre- and perimenopausal patients with aggressive forms of HR+/HER2- mBC, including patients with visceral crisis. Data presented at SABCS: mPFS 24.0 vs. 12.3 months; HR=0.54; p=.0007. 27 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#28Company overview Financial review 2023 priorities Appendix GROWTH ZolgensmaⓇ maintains leading share in patients with SMA <2 years of age¹; Q4 growth impacted by prior year prevalent boluses Sales evolution USD m, % cc Ex-US US +5% -5% 342 1,351 1,370 309 224 882 936 209 118 100 469 434 Q4 2021 Q4 2022 FY 2021 FY 2022 1. Based on US data. 28 Investor Relations | Q4 2022 Results zolgensma® Markets mainly incident patient population Maintaining leader share (>90% US) in <2 years Q4 sales decline due to prior year prevalent boluses in ex-US markets (Europe/Canada) FY sales USD 1.4bn (+5% cc) Continued efforts to increase newborn screening ex-US (45% in Europe; >99% in US) IT development on track - Ph3 STEER and STRENGTH enrolling NOVARTIS | Reimagining Medicine#29Company overview Financial review 2023 priorities Appendix Leqvio® – we are continuing to progress the launch in Q4... - GROWTH LEQVIO® Addressing non-clinical barriers Access Patients covered at or near label1 76% Adoption Facilities having ordered LeqvioⓇ +21% Adherence Patients coming for 2nd dose within <95 days4 Adoption 75% HCPS3 with LeqvioⓇ experience +50% FY sales USD 112 million ORION-3 data and publication ■ Strong long-term safety profile ■ Effective/sustained reductions in LDL-C over 4 years ■ At any time throughout the trial -80% of patients reached LDL-C <70mg/dL Ph3 secondary prevention CVRR studies (ORION-4/V2P) ongoing Ph3 primary prevention CVRR study expected start H1 2023 1,700 1,400 7,200 4,800 Q3 2022 HCP Q3 2022 Q4 2022 healthcare professional. Q4 2022 *Leqvio® is administered initially, again V2P-VICTORION-2-PREVENT. 1. As of January 3, 2022. 2. Either an alternate site of care or a physician practice. 3. Either prescribe LeqvioⓇ to a patient based on service center data, data on file or 4. Refers to average duration in between doses. Based on IQVIA and data shared by infusion management and ambulatory infusion center companies. **Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a license agreement with Alnylam Pharmaceuticals. have ordered through Free Trial Offer program. at 3 months, and then once every 6 months. 29 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#30Company overview Financial review 2023 priorities Appendix expect steady ramp in 2023 similar to Entresto® US trajectory GROWTH LEQVIO® LeqvioⓇ in line with initial EntrestoⓇ launch US monthly sales evolution USD m 50 50 40 40 30 30 20 20 10 10 Leqvio® EntrestoⓇ или 2023 focus US: Accelerate adoption Enable new facilities to order LeqvioⓇ (breadth) Accelerate growth among prescribers (depth) Support HCPs with acquisition/reimbursement process Expect gradual conversion from Free Trial offer Ex-US: Continue rollout Expand prescriber breadth in UK Anticipate regulatory approval in additional geographies including China (Q4 2023) 0 6 12 18 Prepare for anticipated launches in China/Japan/Spain 24 30 36 Months since launch *Leqvio® is administered initially, again at 3 months, and then once every 6 months. **Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a license agreement with Alnylam Pharmaceuticals. 30 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#31Company overview Financial review 2023 priorities Appendix PluvictoⓇ rapid uptake in US reflects very strong demand, driven by significant unmet need and impressive clinical profile Sales evolution Global sales, USD m 80 60 179 2 Q1 10 10 Q2 Q3 Q4 2022 NBRX new to brand prescriptions. mCRPC metastatic castration-resistant prostate cancer. 31 Investor Relations | Q4 2022 Results GROWTH PLUVICTO FY sales USD 271 million (almost entirely US) NBRx share 18% in post-taxane mCRPC 160+ unique accounts in US treated with Pluvicto in 2022 More than 75% of insured lives covered (across Medicare, Medicaid and private payers) Permanent A code effective in October Approved in EU for mCRPC post-taxane NOVARTIS | Reimagining Medicine#32Company overview Financial review 2023 priorities Appendix PluvictoⓇ manufacturing capacity is set to significantly expand in 2023 with bringing Millburn and Indianapolis on-line Expected coverage by end 2023 Manufacturing site1: Ivrea Millburn Indianapolis Zaragoza Commercial US, EU, ROW² Canada, US3 US3 Clinical EU, ROW Canada, US, EU EU, ROW² Targeting capacity of at least 250k doses annually for 2024+ 1. Additional manufacturing sites in Asia under evaluation. 2. Dependent on regulatory approval. 3. Expected in H2 2023. 32 Investor Relations | Q4 2022 Results GROWTH P PLUVICTO NOVARTIS | Reimagining Medicine#33Company overview Financial review 2023 priorities Appendix ScemblixⓇ launch off to a strong start Sales evolution USD m Ex-US US 31 25 52 10 444 41 42 37 25 29 25 Q1 Q2 Q3 Q4 2022 1. IQVIA: US Oct 2022 rolling three months 3L+ new patient start share. 33 Investor Relations | Q4 2022 Results GROWTH OSCEMBLIX® (asciminib) 20 mg. 40 mg tablets FY sales USD 149 million US sales driven by patients resistant/intolerant to other TKIs; CML 3L+ NBRx share at 29%1 Global rollout ongoing with approval in 40 countries; access pathways in 9, negotiations ongoing in 30+ ASCEND IIT presented at ASH, showing promising preliminary results and consistent tolerability in 1L CML ASC4FIRST (1L registrational study) completed enrollment ahead of plan, readout expected 2024 NOVARTIS | Reimagining Medicine#34Company overview Financial review 2023 priorities Appendix Harry Kirsch Chief Financial Officer Financial review and 2023 guidance 34 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#35Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE 2022 financial results in line with guidance; ahead on Core Oplnc Group full year guidance (Q3 earnings October 2022) In cc FY 2022 vs. PY Innovative Medicines Sales to grow mid single digit +4% Core Opinc to grow mid to high single digit, ahead of sales +8% Sandoz Sales to grow low to mid single digit Core Oplnc to grow low single digit +4% -1% Group Sales to grow mid single digit Core Oplnc to grow mid single digit +4% +8% 35 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#36Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE 2022 performance continues our track record of consistent top-line growth and core margin expansion for Innovative Medicines (IM) IM Sales1 USD bn, % CAGR CC +5% IM Core Oplnc¹ USD bn, % CAGR CC +10% 42.0 15.2 15.2 41.3 39.0 37.7 13.6 12.7 +4% +6% +4% CC CC CC +11% +10% +8% CC CC CC IM Core Margin¹ (%), growth bps cc 33.5 +220bps 35.0 +130bps +130bps 36.9 36.2 FY 2019 FY 2020 FY 2021 FY 2022 FY 2019 FY 2020 FY 2021 FY 2022 FY 2019 FY 2020 FY 2021 FY 2022 1.2022 FY Sales growth +4% cc and -2% USD, 2022 FY Core Oplnc growth +8% cc and 0% USD. 36 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#37Company overview Financial review 2023 priorities Appendix Solid Q4 and FY performance Group1 USD million Q4 Change vs. PY 2022 FY 2022 % USD % cc % USD Change vs. PY % cc Net Sales 12,690 -4 3 50,545 -2 4 Core Operating income 4,030 6 15 16,665 0 8 Operating income 1,949 -24 -14 9,197 -21 -13 Net Income 1,466 -91 -90 6,955 -71 -67 Growth ex. prior year Roche income -12 2 -20 -9 Core EPS (USD) 1.52 9 19 6.12 -3 0 Growth ex. prior year Roche income 12 23 5 14 EPS (USD) 0.69 -91 -89 3.19 -70 -66 Growth ex. prior year Roche income -8 7 -17 -7 Free Cash Flow 3,552 17 11,945 -10 Growth ex. prior year Roche dividend 17 -6 FINANCIAL PROFILE 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 50 of the Condensed Financial Report. A table showing the Q4 2022 and FY 2022 key figures excluding Roche can be found on page 3 and 9 and a reconciliation of 2021 IFRS results and non-IFRS measures core results to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 59 of the Condensed Interim Financial Report. 37 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#38Company overview Financial review 2023 priorities Appendix Novartis proposes 26th consecutive dividend increase to the AGM: 3.20 CHF / share¹ 2022 Dividend yield 3.8%² Dividend growth 3.2%3 CHF dividend USD dividend4 3.5 3.0 2.5 2.0 1996-2022 CAGR CHF: 7.4% USD: 9.3%4 1.5 1.0 0.5 0.0 T FINANCIAL PROFILE 2022 proposal: CHF 3.20 USD 3.464 2021: CHF 3.10 USD 3.334 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 1. Proposal to shareholders at the 2023 Annual General Meeting, taking place on March 7, 2023 2. Based on closing share price of CHF 83.59 at end of business year 2022 (December 30, 2022) 3. In CHF 4. Historical dividends per share converted at historical exchange rates at the dividend payment dates as per Bloomberg; for 2022, translated into US dollars at the FX rate of CHF/USD of 1.081, as of December 31, 2022 38 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#39Company overview Financial review 2023 priorities Appendix Continuing core margin improvements for Group driven by IM Innovative Medicines Sandoz Group Q4 2022 Core operating FY 2022 Core operating FINANCIAL PROFILE Net sales change vs. PY income change vs. PY Core margin Core margin change vs. PY Net sales change vs. PY Core margin income change vs. PY Core margin change vs. PY (in % cc)1 (in % cc) 1 (%)1 (%pts cc)1 (in % cc)1 (in % cc)1 (%) 1 (%pts cc)1 3 14 36.4 3.5 4 8 36.9 1.3 0 -18 16.8 -3.8 4 -1 20.6 -1.1 3 15 31.8 3.5 4 8 33.0 1.3 IM - Innovative Medicines. 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Interim Financial Report. 39 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine#40Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE Sandoz returns to growth in 2022; planned spin-off on track for H2 Driven by Biopharma and ex-US sales FY performance¹ Sales USD 9.2bn (+4%) Biopharma grew 9% and Retail 4% Strong ex-US sales growth: ■ EU: USD 4.9bn (+4%) ■ ROW: USD 2.5bn (+9%) ■ US: USD 1.8bn (-4%) Core Oplnc (-1%) impacted by inflationary pressures on input costs and higher SG&A Key growth drivers for 2023 and beyond Share gains across geographies Two potential US biosimilar approvals expected in H2 2023 Launches, targeting USD 80bn originator sales (2030) with strong pipeline of 15+ biosimilar assets Bolt-on BD&L and M&A On track for planned spin-off in H2 2023 Final transaction requires Novartis AG BoD and shareholder approval Carve-out financials to be provided ahead of CMD Expected to be tax neutral to Novartis and the majority of our institutional shareholders 1. All growth rates in constant currencies (cc). 40 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#41Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE Novartis excluding and including Sandoz 2023 full year guidance Expected, barring unforeseen events; growth vs. PY in cc Innovative Medicines (IM) Novartis ex. Sandoz (IM + Corporate) Novartis incl. Sandoz (IM + Sandoz + Corporate)1 Key assumptions: Sales expected to grow low-to-mid single digit Core Oplnc expected to grow mid-to-high single digit Sales expected to grow low-to-mid single digit Core Oplnc expected to grow mid-to-high single digit Sales expected to grow low-to-mid single digit Core Oplnc expected to grow mid single digit ■ Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics, and that no SandostatinⓇ LAR generics enter in the US in 2023 ■ We continue to expect that the planned Sandoz spin-off is completed in H2 2023 1. Novartis Group guidance, assuming Sandoz would remain within the Group for the entire FY 2023 41 Investor Relations | Q4 2022 Results U NOVARTIS | Reimagining Medicine#42Company overview Financial review 2023 priorities Appendix Sandoz 2023 and mid-term guidance Expected, barring unforeseen events; growth vs. PY in cc 2023 Mid-term Sales expected to grow low-to-mid single digit Core Oplnc expected to decline low double digit, reflecting required stand-up investments to transition Sandoz to a separate company and continued inflationary pressures Sales expected to grow low-to-mid single digit CAGR Core Oplnc margin expected to expand to mid 20s, continuously progressing from the low 2023 base driven by continued Sales growth and operational efficiencies Key assumptions: We continue to expect that the planned Sandoz spin-off is completed in H2 2023 Note: after completion of planned Sandoz spin-off, Core Oplnc guidance will be expressed in terms of core EBITDA. 42 Investor Relations | Q4 2022 Results FINANCIAL PROFILE 1 NOVARTIS | Reimagining Medicine#43Company overview Financial review 2023 priorities Appendix FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full year guidance Core Net Financial Result Expenses expected to be broadly in line vs. 2022 Core Tax Rate Expected to be broadly in line vs. 2022 43 Investor Relations | Q4 2022 Results FINANCIAL PROFILE NOVARTIS | Reimagining Medicine#44Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE Group Core Oplnc to grow mid single digit as sales growth and SG&A savings partly offset by Gx erosion and Sandoz stand-up costs 2023 key drivers of core operating income (Group) Vs. PY (cc) Illustrative - Impact of inflation expected to continue in 2023 Gx erosion expected to increase due to GilenyaⓇ US and LucentisⓇ EU Stand-up investments to transition Sandoz to a standalone company + In-market growth drivers to continue growing strongly + Recent launches to further accelerate + China growth expected to accelerate benefiting from return to normal in H2 + Simplified organizational model to deliver continued SG&A savings + Ongoing productivity programs. - - 44 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#45Company overview Financial review 2023 priorities Appendix Expected currency impact for 2023 Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2023 FX impact on net sales I I 0 to +1 FX impact on core operating income I I I -3 to -4 -7 -6 -9 -8 I Q4 FY Q1 FY Q4 FY 2022 2023 2022 I I I Actual Simulation 45 Investor Relations | Q4 2022 Results FINANCIAL PROFILE -5 -1 Q1 FY 2023 NOVARTIS | Reimagining Medicine#46Company overview Financial review 2023 priorities Appendix Vas Narasimhan, M.D. Chief Executive Officer 46 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#47Company overview Financial review 2023 priorities Appendix Creating impact through fulfilling unmet medical need by delivering innovative medicines to as many people possible ~290 million patients reached with Innovative Medicines and Novartis Global Health, and an additional -453 million patients reached with Sandoz ~150 pipeline projects further expanding patient reach ~40 new drug approvals over the last 20 years, delivering innovative medicines Recent innovation highlights: LeqvioⓇ ASCVD ScemblixⓇ CML PluvictoⓇ Prostate cancer First gene, siRNA and radioligand therapies (at scale), fulfilling unmet medical need iptacopan PNH and C3G 47 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#48Company overview Financial review 2023 priorities Appendix Novartis priorities for 2023 and beyond 1 Transforming to a pure-play IM company CONCLUSION Prioritizing pipeline in specific DAs to 5 high-value NMEs across our 5 core TAs 2 Focusing on 5 core TAs, technology platforms and the US 3 Establishing 9 key brands. with multi-$bn potential The most trusted and valued medicines company Continuing to deliver 6 improved financials Continuing with shareholder- 7 focused capital allocation 4 Improving R&D productivity (e.g. iptacopan, PluvictoⓇ) 48 Investor Relations | Q4 2022 Results Strengthening foundations - 8 ESG/Human Capital 1 NOVARTIS | Reimagining Medicine#49Company overview Innovation: Pipeline overview Appendix Financial review 2023 priorities Appendix Abbreviations Innovation: Clinical trials 49 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#50Company overview Financial review Innovation: Pipeline overview 2022 events¹ NME Lead Regulatory H1 Pluvicto™ mCRPC (US/EU ✓) decisions H1 VijoiceⓇ PROS (US) H2 Scemblix 3L CML (JP/EU✓) H2 tislelizumab ESCC 2L (US) 10 H1/H2 JakaviⓇ acute & chronic GVHD (EU /JPx13) H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU ✓ /JP✓ ) H1/H2 BeovuⓇ DME (US/EU/JP ✓) ensovibep COVID-19 (US) H1/H2 Cosentyx® HS (EU/US ✓) H1/H2 tislelizumab NSCLC (EU/US x²) Submissions H1 H2 tislelizumab 1L Nasopharyngeal cancer (US x2) H2 Cosentyx Psoriatic Arthritis IV (US) 12 Submissions- H2 enabling readouts H2 canakinumab NSCLC Ph3 CANOPY-A (PE not met) iptacopan PNH Ph3 APPLY-PNH✓ H2 Pluvicto™ pre-taxane mCRPC Ph3 PSMAfore³✓ 2023 priorities Appendix Abbreviations Innovation: Clinical trials ✓ Achieved to plan X Not achieved to plan Other readouts H1 sabatolimab HR-MDS Ph2 √4 H1 CosentyxⓇ Lichen planus Ph2 PRELUDE5✓ (PE not met) H1 CosentyxⓇ axSpA IV Ph3 INVIGORATE-1 ✓ H1 icenticaftor COPD Ph2b √6 H2 UNR844 presbyopia Ph2 READER (PE not met) Ph3/pivotal study starts H1 CosentyxⓇ peripheral SpA x7 H1 OAV101 SMA IT STEER ✓ H1 ensovibep COVID-19 (EMPATHY Part B) x8 H2 JDQ443 NSCLC mono H2 ianalumab Sjögren's Syndrome ✓ H2 ianalumab Lupus Nephritis ✓ H2 ociperlimab solid tumors x H2 PluvictoⓇ nmCRPC x11 H2 YTB323 2L DLBCL9x H2 OAV101 SMA IT Ph3b STRENGTH ✔ PE: Primary Endpoint Note: KisqaliⓇ NATALEE Ph3 readout removed (2023 event as shared at Q1 2023). 1. Selected. 2. No US submission planned. 3. Could move to early 2023. 4. Submission will be based on Ph3 results. 5. Primary endpoint at Wk16 not met. 6. Ph2b DRF demonstrated dose response across multiple endpoints, study results presentation end 2022. Out-licensing planned. 7. Strategy update. 8. No definite start date for the IV Ph3 clinical trial can be provided at this time. 9. Development strategy updated. 10. FDA deferred action pending completion of required inspections. 11. Ph3 in nmCRPC shifting to Ph2, with FPFV in 2023. 12. Submission included also ankylosing spondylitis IV and non-radiographic axial SpA IV. 13. Base case approval moved to H1 2023. 50 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#51Company overview Financial review Innovation: Pipeline overview 2023 expected key events Regulatory decisions Cosentyx® HS CosentyxⓇ 2 ml Al Cosentyx® IV Leqvio® Hypercholesterolemia Submissions Iptacopan PNH (US/EU/JP) PluvictoⓇ mCRPC, pre-taxane (US) Readouts KisqaliⓇ HR+/HER2- BC (adj) Iptacopan IgAN Ph3 Ph3 starts Iptacopan C3G Ph3 Iptacopan in IC-MPGN LeqvioⓇ CVRR primary prevention lanalumab in immune thrombocytopenia lanalumab in systemic lupus erythematosus 2023 priorities Appendix Innovation: Clinical trials Abbreviations H1 2023 H2 2023 EU US US US JP, China US/EU JP Ph3 Ph3 Ph3 US NATALEE Ph3 FIR APPLAUSE-IgAN Ph3 Ph3 APPEAR-C3G Ph3 Ph3 HS hidradenitis suppurativa. PNH - paroxysmal nocturnal hemoglobinuria. mCRPC metastatic castration-resistant prostate cancer. FIR - first interpretable results. IgAN-immunoglobulin A nephropathy. C3G complement 3 Glomerulopathy. IC-MPGN - immune complex membranoproliferative glomerulonephritis. 51 Investor Relations | Q4 2022 Results INNOVATION U NOVARTIS | Reimagining Medicine#52Company overview Financial review Innovation: Pipeline overview 2023 priorities Appendix Innovation: Clinical trials Abbreviations Our pipeline projects at a glance Innovative Medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular Others Ophthalmology Respiratory & Allergy Global Health Biosimilars¹ 1. Selected disclosed, internal projects. 52 Investor Relations | Q4 2022 Results Phase 1/2 Phase 3 Registration Total 100 42 8 150 24 15 3 42 21 8 0 29 23 7 4 34 5 LO 5 0 10 8 19 52 5 1 14 2 0 21 5 1 0 6 3 0 0 3 11 1 0 12 0 2 0 2 Total 100 44 8 152 1 NOVARTIS | Reimagining Medicine#53Company overview Innovation: Pipeline overview Financial review Novartis pipeline in Phase 1 Solid tumors Code Name 177Lu-NeoB 225AC-PSMA-617 Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA 2023 priorities Appendix Innovation: Clinical trials Abbreviations Hematology Indication(s) Code Multiple solid tumors ADPT03 Metastatic castration-resistant prostate cancer Colorectal cancer (combos) HDM201 Name ADPT03 HDM201 (combos) JBH492 JBH492 Renal cell carcinoma Cancers JEZ567 JEZ567 MAK683 Unveal melanoma MBG453 MAK683 sabatolimab Mesothelioma MIK665 MIK665 KRAS G12C mutated solid tumors PIT565 PIT565 Solid tumors VAY736 ianalumab + ibrutinib BAFF-R inhibitor Solid tumors VOB560 VOB560 NSCLC Solid tumors WVT078 YTB323 WVT078 rapcabtagene autoleucel CD19 CAR-T Solid tumors AAA603 AAA817 ADPT01 ADPT01 DFF332 DFF332 HIF2A inhibitor DKY709 DKY709 + spartalizumab DYP688 DYP688 IAG933 IAG933 JDQ443 JDQ443 Novel immunomodulatory agent GNAQ,GNA11 antagonist. KRAS inhibitor KAZ954 KAZ954 KFA115 KFA115 MGY825 MGY825 NIS793 NIS793, spartalizumab Novel immunomodulatory Agent TGFB inhibitor NIZ985 NIZ985, spartalizumab IL-15 agonist NZV930 NZV930, spartalizumab, NIR178 TNO155 TNO155 VPM087 WNT974 gevokizumab WNT974+ spartalizumab CD73 antagonist SHP2 inhibitor IL-1 beta antagonist Porcupine inhibitor Solid tumors Solid tumors (combo) Cardiovascular Colorectal cancer, 1st line Solid tumors Code XXB750 Name XXB750 Immunology Others Code Name FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 NG1226 NGI226 Mechanism Indication(s) Non-alcoholic steatohepatitis (NASH) Autoimmune indications Systemic lupus erythematosus Tendinopathy Code Name Global Health EDI048 EYU688 EDI048 EYU688 KAF156 INE963 ganaplacide INE963 Neuroscience Code NIO752 Ophthalmology Name NIO752 Mechanism Indication(s) MHU650 MHU650 Tau antagonist Progressive supranuclear palsy 53 Investor Relations | Q4 2022 Results 30 lead indications Lead indication Mechanism BCL11A MDM2 inhibitor CD123 CAR-T EED inhibitor TIM3 antagonist MCL1 inhibitor Indication(s) Sickle cell anemia Hematological malignancy Hematological malignancy Acute myeloid leukemia Cancers Low risk myelodysplastic syndrome Hematological malignancies B-cell malignancies Hematological malignancy (combo) Cancers Multiple myeloma Adult ALL Mechanism NPR1 agonist Indication(s) Cardiovascular diseases Mechanism CpPI(4)K inhibitor NS4B inhibitor Non-artemisinin plasmodium falciparum inhibitor Indication(s) Cryptosporidiosis Dengue Malaria prophylaxis Malaria, uncomplicated Diabetic eye diseases NOVARTIS | Reimagining Medicine#54Company overview Innovation: Pipeline overview Financial review Novartis pipeline in Phase 2 Solid Tumors Code AAA601 Name LutatheraⓇ Mechanism Indication(s) Radioligand therapy target SSTR GEPNET, pediatrics Ad2AR inhibitor, PD1 inhibitor JDQ443 JDQ443 KRAS inhibitor NIR178 NIS793 NIS793 TNO155 TNO155 NIR178, spartalizumab TGFB inhibitor SHP2 inhibitor 1L ES-SCLC Glioblastoma NSCLC (combo) Cancers 1L metastatic colorectal cancer Solid tumors (single agent) 2023 priorities Appendix Innovation: Clinical trials Abbreviations 28 lead indications Lead indication Hematology Code ABL001 Name ScemblixⓇ INC424 JakaviⓇ LNP023 iptacopan MBG453 sabatolimab PHE885 PHE885 PKC412 Rydapt YTB323 rapcabtagene autoleucel Cardiovascular Mechanism BCR-ABL inhibitor JAK1/2 inhibitor CFB inhibitor TIM3 antagonist BCMA cell therapy Multi-targeted kinase inhibitor. CD19 CAR-T Indication(s) Chronic myeloid leukemia, 2L, pediatrics Acute GVHD, pediatrics Immune thrombocytopenia Unfit acute myeloid leukemia Acute myeloid leukemia, maintenance 4L multiple myeloma Acute myeloid leukemia, pediatrics 1L high-risk large B-cell lymphoma Chronic GVHD, pediatrics Code Hidradenitis suppurativa Name CFZ533 iscalimab HSY244 HSY244 LNP023 iptacopan MBL949 MBL949 TIN816 TIN816 XXB750 XXB750 Mechanism CD40 inhibitor CFB inhibitor ATP modulator Immunology Code Name CFZ533 iscalimab CMK389 CMK389 DFV890 DFV890 Mechanism CD40 inhibitor IL-18 inhibitor NLRP3 inhibitor LNA043 LNA043 ANGPTL3 agonist LOU064 remibrutinib BTK inhibitor Indication(s) Sjögren's Atopic dermatitis Osteoarthritis Familial cold auto-inflammatory syndrome Knee osteoarthritis Osteoarthritis (combos) Food allergy Hidradenitis suppurativa Sjögren's Others NPR1 agonist Indication(s) Lupus nephritis Type 1 diabetes mellitus Atrial fibrillation Lupus nephritis Obesity related diseases Acute kidney injury Hypertension LRX712 LRX712 LYS006 LYS006 MAS825 MAS825 MHV370 MHV370 QUC398 QUC398 VAY736 ianalumab Neuroscience Code Anti-inflammatory Osteoarthritis Colitis ulcerative Hidradenitis suppurativa NLRC4-GOF indications Sjögren's Mixed connective tissue disease Osteoarthritis Autoimmune hepatitis ADAMTS5 inhibitor BAFF-R inhibitor Systemic lupus erythematosus Mechanism Name ADPT06 ADPT06 BLZ945 sotuletinib CSF-1R inhibitor DLX313 MIJ821 DLX313 (UCB0599) onfasprodil 1. Gyroscope acquisition. Alpha-synuclein Inhibitor NR2B negative allosteric modulator Indication(s) Cognitive impairment Amyotrophic lateral sclerosis Parkinson's disease Major depressive disorder with acute suicidal ideation or behavior Code Name Global Health KAE609 cipargamin KAF156 ganaplacide LXE408 LXE408 QMF149 Atectura® SEG101 Adakveo® SKO136 ensovibep Respiratory & Allergy CMK389 CMK389 LTP001 Ophthalmology LKA651 LKA651 LNP023 iptacopan PPY9881 PPY988 PfATP4 inhibitor Non-artemisinin plasmodium falciparum inhibitor Proteasome inhibitor Combo P-selectin inhibitor Multi-specific DARPin IL-18 inhibitor SMURF1 inhibitor EPO inhibitor CFB inhibitor Gene therapy - Complement factor I modulation Mechanism Malaria, severe Malaria, uncomplicated Visceral leishmaniasis Asthma, pediatrics Sickle cell disease, pediatrics Corona virus infection Pulmonary sarcoidosis Pulmonary arterial hypertension Idiopathic pulmonary fibrosis Diabetic eye disease ¡AMD Geographic atrophy 54 Investor Relations | Q4 2022 Results Indication(s) Malaria, uncomplicated U NOVARTIS | Reimagining Medicine#55Company overview Financial review Innovation: Pipeline overview Novartis pipeline in Phase 3 Solid Tumors Code AAA617 2023 priorities Appendix Innovation: Clinical trials Abbreviations Hematology 8 lead indications Lead indication Mechanism BCR-ABL inhibitor Thrombopoietin receptor (TPO-R) agonist CFB inhibitor Indication(s) Chronic myeloid leukemia, 1st line Radiation sickness syndrome Paroxysmal nocturnal hemoglobinuria Atypical hemolytic uraemic syndrome Myelodysplastic syndrome 1L Immune Thrombocytopenia 2L Immune Thrombocytopenia warm Autoimmune Hemolytic Anemia Name Mechanism Indication(s) Pluvicto™ Radioligand therapy target PSMA mCRPC, pre-taxane Metastatic hormone sensitive prostate cancer (mHSPC) AAA6011 LutatheraⓇ BYL719 JDQ443 Piqray® JDQ443 PI3Ka inhibitor KRAS inhibitor LEE011 Kisqali® CDK4/6 Inhibitor NIS793 NIS793 TGFB1 inhibitor VDT482 tislelizumab PD1 inhibitor Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 tumors (GEP-NET 1L G3) Ovarian cancer 2/3L Non-small cell lung cancer HR+/HER2- BC (adj) 1L Metastatic pancreatic ductal adenocarcinoma 1L Nasopharyngeal Carcinoma 1L ESCC Code Name ABL001 ScemblixⓇ ETB115 PromactaⓇ LNP023 iptacopan MBG453 VAY736 sabatolimab ianalumab TIM3 antagonist BAFF-R inhibitor Adj/Neo adj. NSCLC 1L Gastric cancer Immunology 1L Hepatocellular Carcinoma 1L Urothelial Cell Carcinoma Code Name Mechanism AIN457 Cosentyx® IL17A inhibitor IGE025 Xolair® IgE inhibitor. LOU064 remibrutinib BTK inhibitor OGE031 ligelizumab VAY736 ianalumab IgE inhibitor BAFF-R inhibitor Indication(s) Lupus Nephritis Giant cell arteritis Food allergy Chronic spontaneous urticaria Food allergy Sjögren's Lupus Nephritis Localized ESCC 1L Small Cell Lung Cancer Cardiovascular Mechanism siRNA (regulation of LDL-C) CFB inhibitor Code Name KJX839 Leqvio® LNP023 iptacopan TQJ230 pelacarsen ASO targeting Lp(a) Indication(s) CVRR-LDLC IgA nephropathy Hyperlipidemia, pediatrics C3 glomerulopathy Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) (CVRR-Lp(a)) Others Code Name Mechanism Neuroscience Code Name AMG334 AimovigⓇ BAF312 Mayzent LOU064 remibrutinib OAV101 AVXS-101 OMB157 Kesimpta® Mechanism CGRPR antagonist S1P1,5 receptor modulator BTK inhibitor Indication(s) Migraine, pediatrics Multiple sclerosis, pediatrics Multiple sclerosis SMN1 gene replacement therapy SMA IT administration CD20 Antagonist Global Health COA566 Coartem® Ophthalmology RTH258 BeovuⓇ Biosimilars PGH-1 (artemisinin combination therapy) VEGF inhibitor Mechanism Code Multiple sclerosis, pediatrics Name GP2411 denosumab SOK583 aflibercept anti RANKL mAb VEGF inhibitor 1. 177 Lu-dotatate in US. 55 Investor Relations | Q4 2022 Results Indication(s) Malaria, uncomplicated (<5kg patients) Diabetic retinopathy Indication(s) Osteoporosis (same as originator) Ophthalmology indication (as originator) U NOVARTIS | Reimagining Medicine#56Company overview Innovation: Pipeline overview Financial review 2023 priorities Appendix Innovation: Clinical trials Abbreviations Novartis pipeline in registration Solid Tumors Code Name VDT482 tislelizumab Mechanism PD1 inhibitor DRB436 Tafinlar+ MekinistⓇ BRAF inhibitor + MEK inhibitor Indication(s) 2L ESCC Non-small cell lung cancer HGG/LGG, pediatrics Immunology Code Name Mechanism AIN457 CosentyxⓇ IL17A inhibitor IGE025 XolairⓇ IgE inhibitor 1. Approved in US. 56 Investor Relations | Q4 2022 Results Indication(s) Hidradenitis suppurativa Psoriatic arthritis (IV formulation) Axial SpA (IV formulation) Auto-injector Cardiovascular Code LCZ696 Name Entresto® 1 lead indication Lead indication Mechanism Indication(s) Angiotensin receptor/neprilysin Congestive heart failure, pediatrics1 inhibitor NOVARTIS | Reimagining Medicine#57Supplementary Lead Company overview Financial review Innovation: Pipeline overview 2023 priorities Appendix Innovation: Clinical trials Abbreviations Novartis submission schedule New Molecular Entities: Lead and supplementary indications 2023 iptacopan LNP023 PNH JDQ443 2024 JDQ443 2/3L NSCLC (mono) remibrutinib LOU064 CSU sabatolimab MBG453 HR-MDS PluvictoⓇ AAA617 mCRPC, Pre-taxane tislelizumab VDT482 1L Gastric Cancer tislelizumab VDT482 1L ESCC tislelizumab VDT482 1L Hepatocellular Carcinoma tislelizumab VDT482 1L Nasopharyngeal cancer iptacopan LNP023 C3G iptacopan LNP023 IgAN PluvictoⓇ AAA617 mHSPC tislelizumab VDT482 1L Small Cell Lung Cancer tislelizumab VDT482 Localized ESCC 1. Gyroscope acquisition. 57 Investor Relations | Q4 2022 Results 凹 Cardiovascular Immunology Neuroscience Solid tumors Hematology Non-core TA project 2025 NIS793 1L Pancreatic cancer pelacarsen TQJ230 CVRR-Lp(a) 177 Lu-NeoB AAA603 Multiple Solid Tumors. W gevokizumab VPM087 1st line CRC ianalumab VAY736 2L Immune Thrombocytopenia cipargamin KAE609 Malaria severe ganaplacide KAF156 Malaria uncomplicated iscalimab CFZ533 Sjögren's syndrome ligelizumab QGE031 Food allergy LNA043 Knee osteoarthritis libvatrep SAF312 COSP ≥2026 MIJ821 Acute depression rapcabtagene autoleucel YTB323 High-risk large B-cell lymphoma Y LXE408 Visceral leishmaniasis TNO155 Solid tumors XXB750 Hypertension PPY9881 Geographic atrophy ianalumab VAY736 1L Immune Thrombocytopenia ianalumab VAY736 WAIHA ianalumab VAY736 AIH ianalumab VAY736 Sjögren's syndrome cipargamin KAE609 Malaria uncomplicated до Y ianalumab VAY736 Lupus Nephritis ianalumab VAY736 SLE iptacopan LNP023 aHUS JDQ443 JDQ443 NSCLC (Combo) remibrutinib LOU064 Multiple sclerosis remibrutinib LOU064 Y Sjögren's syndrome sabatolimab MBG453 Unfit AML tislelizumab VDT482 Adj/Neo adj NSCLC tislelizumab VDT482 1L Urothelial Cell Carcinoma U NOVARTIS | Reimagining Medicine#58Existing brands Company overview Financial review Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands 2023 priorities Appendix Innovation: Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Solid tumors Hematology Non-core TA project KisqaliⓇ 2023 ribociclib, LEE011 HR+/HER2- BC (adj) Lutathera 177 Lu-oxodotreotide GEP-NET 1L G3 PiqrayⓇ alpelisib, BYL719 Ovarian cancer XolairⓇ omalizumab, IGE025 Food allergy Y Jakavi® 2024 ruxolitinib, INC424 Pediatrics Acute GVHD JakaviⓇ ruxolitinib, INC424 Pediatrics Chronic GVHD 2025 Cosentyx® secukinumab, AIN457 Y GCA Ly LeqvioⓇ KJX839 Ped Hyperlipidemia ScemblixⓇ ABL001 CML 1L ZolgensmaⓇ AVXS-101 OAV101 SMA IT O denosumab GP2411 BioS anti RANKL mAb Adakveo SEG101 Sickle cell disease, pediatrics aflibercept SOK583 BioS Neovascular age-related macular degeneration Coartem® artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg AimovigⓇ erenumab, AMG334 Pediatric Migraine CosentyxⓇ secukinumab, AIN457 Lupus Nephritis KesimptaⓇ2 ofatumumab Multiple sclerosis, pediatrics LeqvioⓇ KJX839 CVRR-LDLC BeovuⓇ brolucizumab, RTH258 Diabetic retinopathy PromactaⓇ eltrombopag, ETB115 Radiation sickness syndrome AtecturaⓇ indacaterol + mometasone, QMF149 Asthma, pediatrics 1. 177 Lu-dotatate in US. 2. Kesimpta and Mayzent: Pediatric study in multiple sclerosis run in conjunction (NEOS). 58 Investor Relations | Q4 2022 Results ≥2026 න MayzentⓇ 2 siponimod, BAF312 Multiple sclerosis, pediatrics RydaptⓇ midostaurin, PKC412 Acute myeloid leukemia, pediatrics ScemblixⓇ ABL001 CML, 2L, pediatrics NOVARTIS | Reimagining Medicine#59Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Clinical Trials Update Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com Oncology Appendix Abbreviations Other 59 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#60Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Cardiovascular Oncology Appendix Abbreviations Other 60 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#61Company overview Innovation: Pipeline overview Cardiovascular iptacopan - CFB inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience NCT04578834 APPLAUSE-IgAN (CLNP023A2301) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Publication IgA nephropathy Phase 3 450 Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine collection) at 9 months Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated over 24 months Arm 1 - LNP023 200mg BID Arm 2 - Placebo BID Primary IgA Nephropathy patients 2023 (primary endpoint for US initial submission, 9 months UPCR) 2025 (24 months) Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: Study Design Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY 61 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#62Company overview Innovation: Pipeline overview Cardiovascular iptacopan - CFB inhibitor NCT03955445 (CLNP023B12001B) Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Oncology iptacopan - CFB inhibitor NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 Appendix Abbreviations Other Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Indication Phase Patients C3 glomerulopathy (C3G) Phase 2 Indication Phase Primary Outcome Measures Target Patients Readout Arms Intervention 27 patients from ongoing Ph2 (sample size from Ph3 pending HA discussions Q1 2021), total patients for this study will increase Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy Patients 68 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) 2023 2025 Milestone(s) Publication TBD Publication Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory 62 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#63Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology LeqvioⓇ - siRNA (regulation of LDL-C) NCT03705234 ORION-4 (CKJX839B12301) Indication Phase 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other Leqvio® - siRNA (regulation of LDL-C) NCT03814187 ORION-8 (CKJX839A12305B) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) Indication Phase 3 Patients Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) 15000 A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arm 1: every 6 month treatment Inclisiran sodium 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) for a planned median duration of about 5 years Arm 2: matching placebo (given bysubcutaneous injection on the day of randomization, at 3 months and then every 6- months) for a planned median duration of about 5 years. Patient population with mean baseline LDL-C ≥ 100mg/dL 2026 Publication TBD 63 Investor Relations | Q4 2022 Results Phase Patients 3275 Primary Outcome Measures Arms Intervention Target Patients Proportion of subjects achieving prespecified low density lipoprotein cholesterol (LDL-C) targets at end of study Safety and tolerability profile of long-term use of inclisiran Inclisiran sodium 300mg on Day 90 and every 180 days for a planned duration of 3 years Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy and risk equivalents (patients from ORION 3, 9, 10 & 11 studies) Readout Milestone(s) Publication 2023 TBD NOVARTIS | Reimagining Medicine#64Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology LeqvioⓇ - siRNA (regulation of LDL-C) NCT04652726 ORION-16 (CKJX839C12301) 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other Leqvio® - siRNA (regulation of LDL-C) NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Indication Hyperlipidemia, pediatrics Indication Phase Phase 3 Phase Phase 3 Patients 150 Patients 12 Primary Outcome Measures Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Primary Outcome Measures Arms Intervention Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630 Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol Arms Intervention Target Patients Target Patients (LDL-C) Readout Milestone(s) 2025 Publication Design publication (O-16/-13) in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022 (actual) Readout Milestone(s) Publication Presentation at EAS May-2022 on O-13/-16 study design (actual) 64 Investor Relations | Q4 2022 Results Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630. Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C) 2025 Design publication (O-16/-13) in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022 (actual) Presentation at EAS May-2022 on O-13/-16 study design (actual) NOVARTIS | Reimagining Medicine#65Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology LeqvioⓇ - siRNA (regulation of LDL-C) 2023 priorities Innovation: Clinical trials Neuroscience NCT05030428 VICTORION-2P (CKJX839B12302) Indication Phase Patients Primary Outcome Measures Arms Intervention Secondary prevention of cardiovascular events in patients with elevated levels of LDL-C Phase 3 15000 1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) Arm 1: Experimental Inclisiran sodium, Subcutaneous injection Arm 2: Placebo Comparator, Placebo Subcutaneous injection Participants with established cardiovascular disease (CVD) Target Patients Readout 2027 Milestone(s) Publication TBD Oncology Appendix Abbreviations Other 65 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#66Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience pelacarsen - Antisense oligonucleotide (ASO) targeting Lp(a) NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Phase 3 8323 Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non- fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL Readout Milestone(s) 2025 Publication TBD 66 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#67Company overview Innovation: Pipeline overview Cardiovascular XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201) Hypertension Indication Phase Phase 2b Patients 170 Primary Outcome Measures week 12 Arms Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Change from baseline in mean 24hr ambulatory systolic blood pressure at Intervention Arm 1 experimental: Dose 1 Arm 2 experimental: Dose 2 Arm 3 experimental: Dose 3 Arm 4 experimental: Dose 4 Arm 5 placebo comparator Resistant Hypertension Patients Target Patients Readout Milestone(s) 2024 Publication TBD Oncology Appendix Abbreviations Other 67 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#68Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology Immunology 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other 68 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#69Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology Cosentyx® - IL-17A inhibitor NCT04181762 SELUNE (CAIN457Q12301) Indication Lupus Nephritis Phase Phase 3 Patients 460 Primary Proportion of subjects achieving protocol-defined CRR Outcome Measures Arms Secukinumab 300 mg s.c. Intervention Placebo s.c. 2023 priorities Innovation: Clinical trials Neuroscience Oncology Cosentyx® - IL-17A inhibitor NCT04930094 GCAPTAIN (CAIN457R12301) Indication Phase Giant cell arteritis Phase 3 Appendix Abbreviations Other Patients 348 Primary Outcome Number of participants with sustained remission Measures Arms Intervention Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) Target Patients Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2025 Final 2026 Readout Milestone(s) Publication TBD Target Patients Readout Milestone(s) 2025 Publication TBD 69 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#70Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor 2023 priorities Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor Appendix Abbreviations Other NCT03217422 AMBER (CVAY736B2201) Indication Autoimmune hepatitis Phase Phase 2 Patients 65 Primary Outcome Alanine aminotransferase (ALT) normalization Measures Arms VAY736 Intervention Target Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Patients Readout 2024 Milestone(s) Publication TBD NCT05126277 SIRIUS-LN (CVAY736K12301) Lupus Nephritis Phase 3 Indication Phase Patients 420 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Frequency and percentage of participants achieving complete renal response (CRR) [ Time Frame: week 72] Arm 1: Experimental -ianalumab s.c. q4w in addition to standard of care (SoC) Arm 2: Experimental - ianalumab s.c. q12w in addition to SoC Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC Patients with active Lupus Nephritis Primary 2027 Publication TBD 70 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#71Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor 2023 priorities Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor Appendix Abbreviations Other Indication NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Indication NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Phase Phase 3 Phase Phase 3 Patients 489 Patients 268 Primary Outcome Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Primary Outcome Measures Measures Target Patients Readout Milestone(s) Publication TBD Arms Intervention Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Primary 2026 Arms Intervention Target Patients Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Arm 2: Placebo comparator Patients with active Sjogren's syndrome Readout Primary 2026 Milestone(s) Publication TBD 71 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#72Company overview Innovation: Pipeline overview Cardiovascular iscalimab - CD40 inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Indication NCT03905525 TWINSS (CCFZ533B2201) Sjögren's syndrome Phase Phase 2 Patients 260 Primary Outcome Measures Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score Arms Intervention Three dose arms of CFZ533 Placebo Target Patients Patients with Sjögren's syndrome Readout Milestone(s) Publication 2022 2023 Oncology Appendix Abbreviations Other 72 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#73Company overview Innovation: Pipeline overview Cardiovascular ligelizumab-IgE Inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience NCT04984876 (CQGE031G12301) Indication Phase Patients Primary Outcome Measures Arms Intervention Food allergy Phase 3 486 1. Proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12 Arm 1: ligelizumab 240 mg subcutaneous injection for 52 weeks Arm 2: ligelizumab 120 mg subcutaneous injection for 52 weeks Arm 3: Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks Arm 4: Placebo 16 weeks and ligelizumab 120 mg/240 mg subcutaneous injection for 36 weeks Arm 5: Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks Participants with a medically confirmed diagnosis of IgE-mediated peanut allergy Target Patients Readout Milestone(s) Publication 2025 TBD 73 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#74Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology LNA043-ANGPTL3 agonist 2023 priorities Innovation: Clinical trials Neuroscience NCT04864392 ONWARDS (CLNA043A12202) Knee osteoarthritis Phase 2 Indication Phase Patients 550 Primary Outcome Measures Arms Intervention Target Patients Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging LNA043 injection to the knee with dosing regimen A LNA043 injection to the knee with dosing regimen B LNA043 injection to the knee with dosing regimen C LNA043 injection to the knee with dosing regimen D Placebo injection to the knee Patients with Symptomatic knee osteoarthritis Primary 2024 Readout Milestone(s) Publication TBD Oncology Appendix Abbreviations Other 74 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#75Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology remibrutinib - BTK inhibitor 2023 priorities Innovation: Clinical trials Neuroscience NCT05030311 REMIX-1 (CLOU064A2301) Chronic spontaneous urticaria Indication Phase Phase 3 Patients 450 Primary Outcome Measures Arms Intervention Change from baseline in UAS7 (Scenario 1 with UAS7 as primary efficacy endpoint) Arm 1: LOU064 (blinded) LOU064 (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2) Arm 2: LOU064 placebo (blinded) LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2) Adult Chronic Spontaneous Urticaria (CSU) patients inadequately controlled by H1-antihistamines Target Patients Readout Milestone(s) 2024 Publication TBD 75 Investor Relations | Q4 2022 Results Oncology remibrutinib - BTK inhibitor Appendix Abbreviations Other NCT05032157 REMIX-2 (CLOU064A2302) Chronic spontaneous urticaria Phase 3 Indication Phase Patients 450 Primary Outcome Measures Arms Intervention Target Patients 1. Change from baseline in UAS7 (Scenario 1 with UAS7 as primary efficacy endpoint) 2. Absolute change in ISS7 an absolute change in HSS7 (Scenario 2 with ISS7 and HSS7 as co-primary efficacy endpoints) Arm 1: LOU064 (blinded) LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open- label) taken orally open label for 28 weeks Arm 2: LOU064 placebo (blinded) LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks Eligible participants randomized to the treatment arms in a 2:1 ratio (arm 1: arm 2) Adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo Readout Milestone(s) Publication 2024 TBD 1 NOVARTIS | Reimagining Medicine#76Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology Neuroscience 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other 76 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#77Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology MayzentⓇ - S1P1,5 receptor modulator NCT04926818 NEOS (CBAF312D2301) Indication Phase Multiple sclerosis, pediatrics Phase 3 Patients 180 Primary Outcome Annualized relapse rate (ARR) in target pediatric participants 2023 priorities Innovation: Clinical trials Neuroscience Measures Arms Intervention Target Patients Readout Milestone(s) Arm 1: Experimental ofatumumab - 20 mg injection/ placebo Arm 2: Experimental siponimod - 0.5 mg, 1 mg or 2 mg/ placebo Arm 3: Active Comparator fingolimod - 0.5 mg or 0.25 mg/ placebo Children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). The targeted enrollment is 180 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ≤40 kg and at least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years. 2026 Publication TBD 77 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#78Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience MIJ821 - NR2B negative allosteric modulator (NAM) NCT04722666 (CMIJ821A12201) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Major depressiv disorder with acute suicidal ideation or behavior Phase 2 195 Change from baseline to 24 hours in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 followed by Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1 followed by Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29 Participants who have suicidal ideation with intent Readout Milestone(s) 2023 Publication TBD 78 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#79Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology remibrutinib - BTK inhibitor 2023 priorities Innovation: Clinical trials Neuroscience Oncology remibrutinib - BTK inhibitor Appendix Abbreviations Other NCT05147220 REMODEL-1 (CLOU064C12301) Indication Multiple sclerosis Indication NCT05156281 REMODEL-2 (CLOU064C12302) Multiple sclerosis Phase Phase 3 Phase Phase 3 Patients 800 Patients 800 Primary Outcome Measures Annualized relapse rate (ARR) of confirmed relapses [Core Part]. ARR is the average number of confirmed MS relapses in a year Primary Annualized relapse rate (ARR) of confirmed relapses Outcome Measures Arms Intervention Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arms Arm 1: Experimental; Remibrutinib - Core Intervention Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Target Patients Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Readout Milestone(s) Publication TBD 79 Investor Relations | Q4 2022 Results Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide - Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib - Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Target Patients Readout Milestone(s) Publication TBD NOVARTIS | Reimagining Medicine#80Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other ZolgensmaⓇ - SMN1 gene replacement therapy ZolgensmaⓇ - SMN1 gene replacement therapy NCT05089656 STEER (COAV101B12301) Indication Phase Spinal muscular atrophy (IT administration) Phase 3 Patients 125 Primary Outcome Measures Arms Intervention Target 1. Change from baseline in Hammersmith functional motor scale - Expanded (HFMSE) total score at the end of follow-up period 1 in treated patients compared to sham controls in the ≥ 2 to < 18 years age group Arm 1: Experimental OAV101. Administered as a single, one-time intrathecal dose Arm 2: Sham Comparator: Sham control. A skin prick in the lumbar region without any medication. Patients Type 2 Spinal Muscular Atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory Patients Readout Milestone(s) 2024 Publication TBD 80 Investor Relations | Q4 2022 Results NCT05386680 STRENGTH (COAV101B12302) Spinal muscular atrophy (IT administration) Phase 3B Indication Phase Patients 28 Primary Outcome Measures Arms Intervention Number and percentage of participants reporting AEs, related AES, SAES, and AESIS [ Time Frame: 52 weeks ] Experimental: OAV-101 Single intrathecal administration of OAV101 at a dose of 1.2 x 10^14 vector genomes Participants with SMA who discontinued treatment With Nusinersen or Risdiplam (STRENGTH) Target Patients Readout Milestone(s) 2024 Publication TBD NOVARTIS | Reimagining Medicine#81Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology Oncology 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other 81 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#82Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor NCT05653349 VAYHIT1 (CVAY736112301) Indication Phase Patients Primary Outcome Measures Arms 1L Immune Thrombocytopenia Phase 3 225 Time from randomization to treatment failure (TTF) 2023 priorities Innovation: Clinical trials Neuroscience Intervention Target Patients Arm 1: Experimental: lanalumab Lower dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 2: lanalumab Higher dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 3: Placebo Comparator administered intravenously with corticosteroids oral or parentally (if clinically justified) Adult patients with primary ITP Readout Milestone(s) 2025 Publication TBD 82 Investor Relations | Q4 2022 Results Oncology NCT05653219 VAYHIT2 (CVAY736Q12301) Indication 2L Immune Thrombocytopenia Phase 3 Appendix Abbreviations Other Time from randomization to treatment failure (TTF) Phase Patients 150 Primary Outcome Measures Arms Intervention Arm 1: Experimental: eltrombopag and ianalumab lower dose Arm 2: Experimental: eltrombopag and ianalumab higher dose Arm 3: eltrombopag and placebo Primary ITP patients who failed steroids Target Patients Readout Milestone(s) Publication 2025 TBD NOVARTIS | Reimagining Medicine#83Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ianalumab - BAFF-R inhibitor 2023 priorities Innovation: Clinical trials Neuroscience NCT05648968 VAYHIA (CVAY736012301) Warm autoimmune hemolytic anemia Phase 3 Indication Phase Patients 90 Primary Outcome Measures Arms Intervention Target Patients Binary variable indicating whether a patient achieves a durable response Durable response: hemoglobin level ≥10 g/dL and ≥2 g/dL increase from baseline, for a period of at least eight consecutive weeks between W9 and W25, in the absence of rescue medication or prohibited treatment Arm 1: experimental lanalumab low dose (intravenously) Arm 2: experimental lanalumab high dose (intravenously) Arm 3: placebo Comparatorn (intravenously) Previously treated patients with warm Autoimmune Hemolytic Anemia Readout Milestone(s) 2026 Publication TBD 83 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#84Company overview Innovation: Pipeline overview Cardiovascular iptacopan - CFB inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience NCT04889430 APPELHUS (CLNP023F12301) Atypical haemolytic uraemic syndrome Phase 3 Indication Phase Patients 50 Primary Outcome Measures Arms Intervention Target Patients Percentage of participants with complete TMA response without the use of PE/PI and anti-C5 antibody Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan Adult patients with aHUS who are treatment naive to complement inhibitor therapy (including anti-C5 antibody) Readout Milestone(s) Publication 2025 TBD Oncology Appendix Abbreviations Other 84 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#85Company overview Innovation: Pipeline overview Cardiovascular JakaviⓇ - JAK1/2 inhibitor NCT03491215 REACH4 (CINC424F12201) Indication Acute graft versus host disease Phase 2 Financial review Immunology Phase Patients 45 Primary Outcome Measurement of PK parameters Measures Overall Response Rate (ORR) Arms Ruxolitinib 2023 priorities Innovation: Clinical trials Neuroscience Intervention Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation Target Patients Readout 2023 Milestone(s) Publication TBD 85 Investor Relations | Q4 2022 Results Oncology JakaviⓇ- JAK1/2 inhibitor NCT03774082 REACH5 (CINC424G12201) Appendix Abbreviations Other Indication Phase Chronic graft versus host disease Phase 2 Patients 45 Primary Overall Response Rate (ORR) Outcome Measures Arms Ruxolitinib 5mg tablets / pediatric formulation Intervention Target Patients Pediatric subjects with moderate and severe chronic Graft vs. Host disease after allogeneic stem cell transplantation Readout Milestone(s) Publication 2023 TBD NOVARTIS | Reimagining Medicine#86Company overview Innovation: Pipeline overview Cardiovascular JDQ443 - KRAS inhibitor Financial review Immunology NCT05132075 KontRASt-02 (CJDQ443B12301) Indication Non-small cell lung cancer, 2/3L Phase Phase 3 Patients 360 Primary Progression free survival (PFS) Outcome Measures Arms 2023 priorities Innovation: Clinical trials Neuroscience Intervention Target Patients Arm 1 Experimental: JDQ443 Arm 2 Active Comparator: Participant will be treated with docetaxel following local guidelines as per standard of care and product labels Patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination. Readout Milestone(s) 2024 Publication NA 86 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#87Company overview Innovation: Pipeline overview Cardiovascular KisqaliⓇ - CDK4 inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience NCT03701334 NATALEE (CLEE011012301C) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 5101 Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy 2023 Publication TBD 87 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#88Company overview Innovation: Pipeline overview Cardiovascular NIS793 - TGFẞ inhibitor Financial review Immunology NCT04935359 daNIS-2 (CNIS793B12301) Indication Phase 1L metastatic pancreatic ductal Adenocarcinoma Phase 3 Patients 501 Primary Outcome Measures Arms Intervention 2023 priorities Innovation: Clinical trials Neuroscience Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment Randomized part: Overall survival (OS) Safety run-in part: NIS793+gemcitabine+nab-paclitaxel Randomized portion of the study: Arm 1: NIS793+gemcitabine+nab-paclitaxel Arm 2: placebo+gemcitabine+nab-paclitaxel Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line treatment Primary: 2024 Target Patients Readout Milestone(s) Publication NA 88 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#89Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology Piqray® - PI3K-alpha inhibitor NCT04729387 EPIK-O (CBYL719K12301) Indication Ovarian Cancer Phase 3 2023 priorities Innovation: Clinical trials Neuroscience Phase Patients 358 Primary Outcome Measures Arms Intervention Target Patients Progression Free Survival (PFS) based on Blinded Independent Review Committee (BIRC) assessment using RECIST 1.1 criteria Arm 1 Experimental: Alpelisib+olaparib: Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule Arm 2 Active Comparator: Paclitaxel or PLD. Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days. Patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected Readout Milestone(s) 2023 Publication TBD 89 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#90Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other PluvictoⓇ - Radioligand therapy target PSMA PluvictoⓇ - Radioligand therapy target PSMA NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Indication Phase Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 Indication Phase Phase 3 Patients 450 Patients 1126 Primary Radiographic Progression Free Survival (rPFS) Primary Outcome Outcome Measures Measures Arms Radiographic Progression Free Survival (rPFS) Intervention Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% 177 Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or MHSPC settings Target Patients Readout Milestone(s) Publication TBD Primary Analysis: 2022 (actual) Final Analysis: 2025 Arms Intervention Arm 1: 177Lu-PSMA-617 Participant will receive 7.4 GBq (+/- 10%) 177 Lu-PSMA- 617, once every 6 weeks for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Target Patients Readout Milestone(s) Publication Primary Analysis: 2024 TBD 90 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#91Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology RydaptⓇ - Multi-targeted kinase inhibitor 2023 priorities Innovation: Clinical trials Neuroscience NCT03591510 (CPKC412A2218) Acute myeloid leukemia, pediatrics Indication Phase Phase 2 Patients 20 Primary Outcome Measures Arms Intervention Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Target Patients Readout 2026 Milestone(s) Publication TBD Oncology Appendix Abbreviations Other 91 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#92Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology sabatolimab - TIM3 antagonist 2023 priorities Innovation: Clinical trials Neuroscience NCT04150029 STIMULUS-AML1 (CMBG453C12201) Unfit acute myeloid leukaemia Phase 2 Indication Phase Patients 86 Primary Outcome Measures Arms Intervention Target Patients Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy Readout Milestone(s) 2023 Publication TBD 92 Investor Relations | Q4 2022 Results Oncology sabatolimab - TIM3 antagonist NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Indication Phase Myelodysplastic syndrome Phase 3 Patients 500 Primary Overall survival Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Publication TBD Appendix Abbreviations Other Sabatolimab 800 mg + azacitidine 75 mg/m2 Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) 2024 NOVARTIS | Reimagining Medicine#93Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology ScemblixⓇ - BCR-ABL inhibitor NCT04971226 ASC4FIRST (CABL001J12301) Chronic myeloid leukemia, 1st line Phase 3 Indication Phase Patients 402 Primary Outcome Major Molecular Response (MMR) at week 48 Measures 2023 priorities Innovation: Clinical trials Neuroscience Arms Intervention Arm 1: asciminib 80 mg QD Arm 2: Investigator selected TKI including one of the below treatments: - Imatinib 400 mg QD - Nilotinib 300 mg BID - - Dasatinib 100 mg QD - Bosutinib 400 mg QD Patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase Target Patients Readout Milestone(s) 2024 Publication TBD 93 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine#94Company overview Innovation: Pipeline overview Cardiovascular TNO155-SHP2 inhibitor NCT03114319 (CTNO155X2101) Indication Solid tumors (single agent) Phase 1 Financial review Immunology Phase Patients 255 Primary Outcome Measures Arms Intervention Target Patients Number of participants with adverse events Number of participants with dose limiting toxicities Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications Readout Milestone(s) Publication 2024 TBD 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other 94 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#95Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Other Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 95 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#96Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology 2023 priorities Innovation: Clinical trials Ophthalmology Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 96 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#97Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology BeovuⓇ - VEGF Inhibitor NCT04278417 (CRTH258D2301) Indication Diabetic retinopathy Phase 3 Change from Baseline in BCVA Phase Patients 706 Primary Outcome Measures Arms Financial review Immunology Intervention Target Patients Arm1: RTH258 (brolucizumab) 6 mg/50uL Arm2: Panretinal photocoagulation laser initial treatment followed with additional PRP treatment as needed Patients with proliferative diabetic retinopathy Readout Milestone(s) 2024 Publication TBD 2023 priorities Innovation: Clinical trials Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 97 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#98Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology libvatrep - TRPV1 antagonist NCT04630158 SAHARA (CSAF312B12201) Chronic ocular surface pain Phase 2 Indication Phase Patients 150 Primary Outcome Change in mean pain severity Visual Analog Scale Measures 2023 priorities Innovation: Clinical trials Neuroscience Global Health Arms Intervention Target Patients Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops, twice daily Subjects with CICP persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. Readout Milestone(s) 2023 Publication 2023 98 Investor Relations | Q4 2022 Results Appendix Abbreviations Oncology Other Biosimilars 1 NOVARTIS | Reimagining Medicine#99Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology Global Health 2023 priorities Innovation: Clinical trials Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 99 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#100Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology Adakveo® - P-selectin inhibitor NCT03474965 SOLACE-Kids (CSEG101B2201) Indication Sickle cell disease, pediatrics Phase 2 PK/PD and safety of SEG101 at 5 mg/kg Phase Patients 100 Primary Outcome Measures Arms 2023 priorities Innovation: Clinical trials Neuroscience Global Health Intervention Target Patients Readout Milestone(s) Publication SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion + Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients ≥12 year old) 2024 (pediatric patients <12 year old) 1. Matthew M. Heeney, David C. Rees, Mariane de Montalembert, Isaac Odame, R. Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Raquel Merino Herranz, Julie Kanter; Study Design and Initial Baseline Characteristics in Solace- Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood 2020; 136 (Supplement 1): 22-24. doi: https://doi.org/10.1182/blood-2020-137081 2. Matthew M. Heeney, David C. Rees, Mariane De Montalembert, Isaac Odame, R. Clark Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Nadege Pfender, Julie Kanter; Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood 2021; 138 (Supplement 1): 12. doi: https://doi.org/10.1182/blood-2021-144730 100 Investor Relations | Q4 2022 Results Appendix Abbreviations Oncology Other Biosimilars NOVARTIS | Reimagining Medicine#101Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology cipargamin - PfATP4 inhibitor NCT04675931 KARISMA (CKAE609B12201) Indication Malaria severe Phase 2 Phase Patients 252 2023 priorities Innovation: Clinical trials Primary Outcome Measures Arms Intervention Target Patients Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours) ] Arm 1: experimental, IV KAE609 Dose regimen 1 Arm 2: experimental, IV KAE609 Dose regimen 2 Arm 3: experimental, IV KAE609 Dose regimen 3 Arm 4: active comparator, IV Artesunate Arm 5: Coartem, Standard of care Patients with Malaria, severe Readout Milestone(s) 2024 Publication TBD Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 101 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#102Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Global Health CoartemⓇ - PGH-1 (artemisinin combination therapy) NCT04300309 CALINA (CCOA566B2307) Malaria, uncomplicated (<5kg patients) Phase 3 Indication Phase Patients 44 Primary Outcome Measures Arms Intervention Artemether Cmax Target Patients Experimental: artemether lumefantrine (2.5 mg:30 mg) artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium falciparum malaria Primary outcome measure: 2023 Readout Milestone(s) Publication TBD Appendix Abbreviations Oncology Other Biosimilars 102 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#103Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology ganaplacide - Non-artemisinin plasmodium falciparum inhibitor NCT04546633 KALUMI (CKAF156A2203) Indication Phase Patients Primary Outcome Measures Arms Intervention Malaria, uncomplicated Phase 2 292 PCR-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition Malaria patients 6 months to < 18 years old Target Patients Readout Milestone(s) 2023 Publication TBD 2023 priorities Innovation: Clinical trials Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 103 Investor Relations | Q4 2022 Results 1 NOVARTIS | Reimagining Medicine#104Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology Biosimilars 2023 priorities Innovation: Clinical trials Neuroscience Global Health Appendix Abbreviations Oncology Other Biosimilars 104 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#105Company overview Innovation: Pipeline overview Cardiovascular Ophthalmology Financial review Immunology aflibercept - VEGF inhibitor NCT04864834 Mylight (CSOK583A12301) Ophthalmology indication (as originator) Phase 3 Indication Phase Patients 460 2023 priorities Innovation: Clinical trials Neuroscience Global Health Primary Outcome Measures Arms Intervention Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing charts at an initial distance of 4 meters. The change from baseline in BCVA in letters is defined as difference between BCVA score between week 8 and baseline Arm 1 Biological: SOK583A1 (40 mg/mL) Arm 2 Biological: Eylea EU (40 mg/mL) Patients with neovascular age-related macular degeneration Target Patients Readout 2023 Milestone(s) Publication tbd Appendix Abbreviations Oncology Other Biosimilars 105 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine#106Company overview Financial review Innovation: Pipeline overview Abbreviations 2023 priorities Appendix Innovation: Clinical trials Abbreviations ΑΙ АІН aHUS ALL ALS AML Auto-injector Autoimmune hepatitis atypical Hemolytic Uremic Syndrome Acute lymphoblastic leukemia Amyotrophic lateral sclerosis Acute myeloid leukemia IgAN IPF ITP LBCL BC Breast cancer LN mCRPC MDS IgA nephropathy Idiopathic pulmonary fibrosis Immune thrombocytopenia Large B-cell lymphoma Lupus nephritis Metastatic castration-resistant prostate cancer Myelodysplastic syndrome C3G C3 glomerulopathy MHSPC Metastatic hormone sensitive prostate cancer CART Chimeric androgen receptor T mPDAC Metastatic pancreatic ductal adenocarcinoma CLL Chronic lymphocytic leukemia CML Chronic myeloid leukemia MS NASH Multiple sclerosis CRC Colorectal cancer nmCRPC COPD Chronic obstructive pulmonary disease NPR1 COSP Chronic ocular surface pain nr-axSpA CSU Chronic spontaneous urticaria NSAI CVRR-Lp(a) CVRR-LDLC DME Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) Secondary prevention of cardiovascular events in patients with elevated levels of LDLC Diabetic macular edema NSCLC Non-alcoholic steatohepatitis Non-metastatic castration-resistant prostate cancer Natriuretic peptide receptor 1 Non-radiographic axial spondyloarthritis Non-steroidal aromatase inhibitor Non-small cell lung cancer OS Overall survival PFS Prefilled syringe DLBCL Diffuse large B-cell lymphoma refractory PNH Paroxysmal nocturnal haemoglobinuria ESCC FL GCA GVHD GRPR HCC HD Esophageal squamous-cell carcinoma Follicular lymphoma Giant cell arteritis Graft-versus-host disease Gastrin releasing peptide receptor Hepatocellular carcinoma Huntington's disease PsA Psoriatic arthritis rHR Resistant hypertension rMS rPFS SLE Relapsing multiple sclerosis Radiographic progression free survival Systemic lupus erythematosus SMA Type 1 Spinal muscular atrophy (IV formulation) HR LBCL High risk large B-cell lymphoma SpA IA Interim analysis T1DM SMA Type 2/3 Spinal muscular atrophy (IT formulation) Spondyloarthritis Type 1 Diabetes mellitus iAMD Intermediate age-related macular degeneration WAIHA Warm autoimmune hemolytic anemia IC-MPGN Immune complex membranoproliferative glomerulonephritis 106 Investor Relations | Q4 2022 Results U NOVARTIS | Reimagining Medicine